Medical Doctor Program year 2020 Reported 2019–2020 Source: CMS Open Payments, 2026 publication

Eric Tompkins

Gastroenterology Anchorage, AK Medical Doctor

NPI 1902888688 CMS profile 1214635

2841 Debarr Road, Suite 50, Anchorage, AK 99508

Open in the dashboard

General payments

$127

7 records reported · program years 2019–2020

Research payments

$0

Paid to them · None reported · program years 2019–2020

Ownership & investment interest

$0

None reported

Through program year 2020, Eric Tompkins of Anchorage, AK is reported in the CMS Open Payments database as having received $127 across 7 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 11th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2020 General $71 4
2019 General $56 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eric Tompkins
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Eric Tompkins were reported at $0. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Eric Tompkins Gastroenterology median Middle half National median
2019 $56 $417 $126–$1,100 $163
2020 $71 $224 $74–$624 $114
2021 $0 $352 $106–$1,054 $132
2022 $0 $448 $129–$1,270 $149
2023 $0 $533 $150–$1,390 $160
2024 $0 $605 $160–$1,606 $164
2025 $0 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2020
  1. AbbVie, Inc. $54 3 payments
  2. Allergan Inc. $41 2 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $19 1 payment
  4. QOL Medical, LLC $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2020
  1. Food and Beverage $127 7 payments
Products named General payments · program years 2019–2020
  1. ZENPEP $41 2 payments
  2. MAVYRET $37 2 payments
  3. Entyvio $19 1 payment
  4. HUMIRA $16 1 payment
  5. Sucraid $13 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

466

Median for Gastroenterology: 569

Drug cost

$33,097

Median for Gastroenterology: $104,976

Branded share of claims

15.5%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Zenpep Lipase/Protease/Amylase Brand 13 $14,838
Mesalamine Er Mesalamine Brand 32 $9,615
Budesonide Dr Budesonide Brand 27 $3,454
Pantoprazole Sodium Generic 156 $2,245
Omeprazole Generic 96 $1,036
Esomeprazole Magnesium Generic 30 $818
Ondansetron Hcl Generic 13 $373
Tacrolimus Generic 26 $354
Famotidine Generic 23 $163
Furosemide Generic 33 $103

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$154,649

Medicare's payments for the services billed

Medicare patients

316

Average age 71

Services billed

5,194

171 women, 145 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 40%
Diabetes 28%
Ischemic heart disease 24%
Chronic kidney disease 20%
Depression 20%
Heart failure 15%
Atrial fibrillation 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

7 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Alaska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record